Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.
The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...
Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat ... drug sensitivity and treatment paradigms for the affected population. Here, Dewald et al. generated liver-specific DM1 mice ...